Straits Times Index
3,176.51 -11.15 (-0.35%) Nikkei
37,068.35 -1,011.35 (-2.66%) Hang Seng
16,224.14 -161.73 (-0.99%) FTSE 100
7,895.85 +18.80 (+0.24%) Bitcoin USD
63,946.06 -568.90 (-0.88%) CMC Crypto 200
1,371.97 +59.35 (+4.52%)
AstraZeneca PLC (AZNCF)
| Previous close | 138.24 |
| Open | 135.62 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 133.20 - 136.20 |
| 52-week range | 118.16 - 153.10 |
| Volume | |
| Avg. volume | 3,000 |
| Market cap | 211.14B |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | 35.75 |
| EPS (TTM) | 3.81 |
| Earnings date | N/A |
| Forward dividend & yield | 2.86 (2.10%) |
| Ex-dividend date | 22 Feb 2024 |
| 1y target est | N/A |
Insider Monkey20 Countries with the Highest Cancer Survival Rates in the World
In this article, we will be taking a look at the 20 countries with the highest cancer survival rates in the world. If you do not want to learn about the cancer treatment in the US, head straight to the 5 Countries with the Highest Cancer Survival Rates in the World. Navigating the Terrain: The […]
ZacksAstrazeneca (AZN) Could Be a Great Choice
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out.
Business WireIMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial
WILMINGTON, Del., April 16, 2024--Updated exploratory results from the TOPAZ-1 Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care chemotherapy demonstrated a clinically meaningful long-term overall survival (OS) benefit at three years for patients with advanced biliary tract cancer (BTC).
